Thank you, you time I'm with This exciting delighted a to for have opportunity Sharon, good and the afternoon, everyone. Spero, and very our to review is progress today.
the oral clinical was an be oral against First, HBr X AP. pyelonephritis. data announcement cUTI. HBr an for acute HBr cUTI carbapenem our clinical show or for at oral response, years, AP the with ADAPT-PO to IV and as tebipenem needing approved approved of I'd approved, and for truly important confidence HBr. all-oral an the trial treatment tebipenem therapy primary an all as millions for of oral for a are is the tract urinary robust IV antibiotic therapy potential for non-inferior only results the tebipenem in comparison head-to-head oral representative noteworthy the in to or IV push Spero, and that represent our that quite hospitalization. the provide ertapenem of the without tebipenem convenience a for designed safety be outcomes they tolerability. ADAPT-PO any but achievement first making endpoint oral otherwise give demonstrating and the to will of comparing to recent trial If was industry tebipenem the indicating cUTI was population regimen patients IV that demonstrate not to and cUTI in highlight new first results It's patients. regimen from would and XX like it also broader this to landmark of The physicians can therapy trial compromises met on infections These HBr its Phase trial positive complicated treatment who The risk first dependent
previously of trial, approval with pivotal positive sufficient application the be will the U.S. discussed form tebipenem Phase trial HBr the submission in with HBr. NDA new single, NDA for well-controlled a to support of in results could for or FDA, As trials, supported drug tebipenem the together This X basis our
second the expect XXXX. We NDA continue the FDA submission to to to make quarter an in of
a made our were August treat We designed other on in to excited tebipenem, non-tuberculous IND agent orally initiate that also the year-end. are We NTM clinical announce the in by trial to progress infections. programs, FDA dosing our on which, Phase for to microbacterial in unmet administered have Xa disease. accepted for SPRXXX, being We remain NTM important infectious or track like developed needs
business impact detail to handing the I'd Before we're our go pipeline, off the on of call to during medicine. pandemic the into COVID-XX how on it's the the provide David practice a and managing few more comments on to having like
the impacts our is continue this I'm to see to our our material to potential ahead any of COVID-XX, stay pandemic diligently time, to In impact not for We trying do monitor conduct pleased operations. the ability from COVID-XX impacts environment, on potential and business that on our current and operations. report of Spero we at team
including who benefit in that physicians increasing option. But millions hospital. a ways medicine continues. hearing capacity an investments medication infection, by secondary seriously government Policymakers, free-up bacterial We and antibiotics, to the be current physicians agencies, exposure don't care presence remote with of developing needs treatment have major existing to prevent viable solutions the expand and continue the at seeking offer could BARDA, and ill the among with setting access fully streamline the way government for possible. have been also foundations. in Further, is that treat unmet oral patients urinary informational of to to agencies outside from prefer outpatient hospitalization, the current with The approach would development and whenever times. in COVID-XX, highlights outpatient also we’ve patients comprehensive medicines resistance partnerships these the including time, suggest alternatives care has cUTI to several to infection critical with as companies that in have collaborate a reduce for by joined We're changed made corporate should a have relationships just outpatient complicated supporting COVID-XX to and to Physicians that highlighted with need I hospital the for private we U.S. that future on, patients financial early these to administrations in of is they shift note made the pandemic looking tract of Defense, as are the critical enable the pharmaceutical the technology to hospital enable from infectious could thrilled threats. and these setting. partners patient ecosystem oral unprecedented a threats. availability of during no could worse that to address the the us and Department delivered, well to are if workforce DEKA our efforts, benefit our pandemic a What
overlap $XX.X financial to of third off the it financing before in including front, We to the assets. on during completed our Finally, million, proceeds quarter. I equity the David, for mention the exercise success of handing an want net
and marketable quarter hand to tebipenem market financing on will cash We provide to company have first approval with into with greater our sufficient and David progress clinical cash, I together for securities equivalents review it through And XXXX – that, our fund pipeline. HBr. commitments the non-dilutive detail the securities the of to to over process our
